Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T63185
|
|||||
Target Name |
KRas D816V mutant (KRAS D816V)
|
|||||
Synonyms |
K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras
Click to Show/Hide
|
|||||
Gene Name |
KRAS
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
Function |
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24623306, ECO:0000305}.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.6.5.2
|
|||||
Sequence |
MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAG
QEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDL PSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGC VKIKKCIIM Click to Show/Hide
|
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | ASP3082 | Drug Info | Phase 1 | Aggressive cancer | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Degrader | [+] 1 Degrader drugs | + | ||||
1 | ASP3082 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023 Apr;20(4):265-278. | |||||
REF 2 | ClinicalTrials.gov (NCT05382559) A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. U.S.National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.